<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00647348</url>
  </required_header>
  <id_info>
    <org_study_id>MSTC-001</org_study_id>
    <secondary_id>MREC: 07/Q1602/73</secondary_id>
    <secondary_id>2006-006347-31</secondary_id>
    <nct_id>NCT00647348</nct_id>
  </id_info>
  <brief_title>Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis</brief_title>
  <acronym>MS-STAT</acronym>
  <official_title>A Phase II Randomised, Placebo-controlled Clinical Trial of Simvastatin in Patients With Secondary Progressive Multiple Sclerosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether simvastatin at a dose of 80mg can reduce the rate of whole brain
      atrophy, as measured by MRI, over a 2-year time-period when compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has now completed see Primary publication:

      Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive
      multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.

      Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K, Anderson V, Bangham CR,
      Clegg S, Nielsen C, Fox NC, Wilkie D, Nicholas JM, Calder VL, Greenwood J, Frost C, Nicholas
      R.

      Lancet. 2014 Jun 28;383(9936):2213-21. doi: 10.1016/S0140-6736(13)62242-4.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>RCT</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>over-encapsulation of IMP</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in Whole Brain Volume</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Disability (EDSS).</measure>
    <time_frame>24 months</time_frame>
    <description>Score (0 to 10), lower score less disability and better progression. For EDSS, mean score at 24 months was compared between treatment groups using an ANCOVA model adjusting for baseline score and minimisation variables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Disability (MSFC Z Score).</measure>
    <time_frame>24 months</time_frame>
    <description>Negative value implies worsening and a positive value implies improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Disability (MSFC Walk).</measure>
    <time_frame>24 months</time_frame>
    <description>The patient is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the patient has reached the 25-foot mark.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Disability (MSFC Peg Test).</measure>
    <time_frame>24 months</time_frame>
    <description>The patient is seated at a table with a small, shallow container holding nine pegs and a wood or plastic block containing nine empty holes. On a start command when a stopwatch is started, the patient picks up the nine pegs one at a time as quickly as possible, puts them in the nine holes, and, once they are in the holes, removes them again as quickly as possible one at a time, replacing them into the shallow container. The total time to complete the task is recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Disability (MSFC PASAT).</measure>
    <time_frame>24 months</time_frame>
    <description>The PASAT is a measure of cognitive function that assesses auditory information processing speed and flexibility, as well as calculation ability. Single digits are presented every 3 seconds and the patient must add each new digit to the one immediately prior to it. Shorter inter-stimulus intervals, e.g., 2 seconds or less have also been used with the PASAT but tend to increase the difficulty of the task. Score 0 to 60, higher score less disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Impact Specific to the Disease and Rated by the Patient (MSIS-29 Questionnaire Total Score)</measure>
    <time_frame>24 months</time_frame>
    <description>The MSIS-29 is a 29-item self-report measure with 20 items associated with a physical scale and 9 items with a psychological scale. Items ask about the impact of MS on day-to-day life in the past two weeks. All items have 5 response options: 1 &quot;not at all&quot; to 5&quot;extremely&quot;. Each of the two scales is scored by summing the responses across items, then converting to a 0-100 scale where 100 indicates a greater impact of the disease on daily function (worse health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Impact Specific to the Disease and Rated by the Patient (MSIS-29 Questionnaire Physical Score)</measure>
    <time_frame>24 months</time_frame>
    <description>The MSIS-29 is a 29-item self-report measure with 20 items associated with a physical scale and 9 items with a psychological scale. Items ask about the impact of MS on day-to-day life in the past two weeks. All items have 5 response options: 1 &quot;not at all&quot; to 5&quot;extremely&quot;. Each of the two scales are scored by summing the responses across items, then converting to a 0-100 scale where 100 indicates greater impact of disease on daily function (worse health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Impact Specific to the Disease and Rated by the Patient (MSIS-29 Questionnaire Psychological Score)</measure>
    <time_frame>24 months</time_frame>
    <description>The MSIS-29 is a 29-item self-report measure with 20 items associated with a physical scale and 9 items with a psychological scale. Items ask about the impact of MS on day-to-day life in the past two weeks. All items have 5 response options: 1 &quot;not at all&quot; to 5&quot;extremely&quot;. Each of the two scales is scored by summing the responses across items, then converting to a 0-100 scale where 100 indicates a greater impact of the disease on daily function (worse health).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Secondary Progressive Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Simvastatin 80mg OD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>80mg simvastatin oral once daily for 24 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo tablet once daily for 24 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a confirmed diagnosis of multiple sclerosis and at randomisation
             have entered the secondary progressive stage. Steady progression rather than relapse
             must be the major cause of increasing disability in the preceding 2 years. Progression
             can be evident from either an increase of at least one point on the EDSS or clinical
             documentation of increasing disability.

          -  EDSS 4.0 - 6.5 inclusive

          -  Women of childbearing age will be required to use appropriate methods of contraception
             to avoid the unlikely teratogenic effects of simvastatin.

          -  Able to give written informed consent

          -  18 - 65 years

        Exclusion Criteria:

          -  Unable to give informed consent

          -  Primary progressive MS

          -  Those that have experienced a relapse or have been treated with steroids (both i.v.
             and oral) within 3 months of the screening visit. These patients may undergo a further
             screening visit once the 3 month window has expired and may be included if no steroid
             treatment has been administered in the intervening period.

          -  Patient is already taking or is anticipated to be taking a statin.

          -  Any medications that unfavourably interact with statins: fibrates, nicotinic acid,
             cyclosporine, azole anti-fungal preparations, macrolideantibiotics, protease
             inhibitors, nefazodone, verapamil, amiodarone, large amounts of grapefruit juice or
             alcohol abuse.

          -  The use of immunosuppressants (e.g. azathioprine, methotrexate, cyclosporine) or
             disease modifying treatments (avonex, rebif, betaferon, glatiramer) within the
             previous 6 months.

          -  The use of mitoxantrone if treated within the last 12 months.

          -  If the patient has ever been treated with alemtuzumab.

          -  If screening levels of alanine aminotransferase (ALT), aspartate aminotransferase
             (AST) or creatine kinase (CK) are three times the upper limit of normal patients
             should be excluded.

          -  Patient unable to tolerate baseline scan or scan not of adequate quality for analysis
             (e.g. too much movement artefact).

          -  If a female patient is pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Chataway, MB BCh, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MRI Unit, National Society for Epilepsy, Chesham Lane</name>
      <address>
        <city>Chalfont St. Peter</city>
        <state>Buckinghamshire</state>
        <zip>SL9 0RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital, Fulham Palace Road</name>
      <address>
        <city>Hammersmith</city>
        <state>London</state>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brighton &amp; Sussex University Hospitals NHS Trust, Eastern Road</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Chan D, Binks S, Nicholas JM, Frost C, Cardoso MJ, Ourselin S, Wilkie D, Nicholas R, Chataway J. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. Lancet Neurol. 2017 Aug;16(8):591-600. doi: 10.1016/S1474-4422(17)30113-8. Epub 2017 Jun 7.</citation>
    <PMID>28600189</PMID>
  </results_reference>
  <results_reference>
    <citation>Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K, Anderson V, Bangham CR, Clegg S, Nielsen C, Fox NC, Wilkie D, Nicholas JM, Calder VL, Greenwood J, Frost C, Nicholas R. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014 Jun 28;383(9936):2213-21. doi: 10.1016/S0140-6736(13)62242-4. Epub 2014 Mar 19.</citation>
    <PMID>24655729</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2008</study_first_posted>
  <results_first_submitted>May 1, 2019</results_first_submitted>
  <results_first_submitted_qc>November 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 12, 2019</results_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Secondary progressive Multiple Sclerosis</keyword>
  <keyword>Simvastatin</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We are still analysing post-hoc data. The International Progressive MS Alliance have access to some of the data.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>next 2 years</ipd_time_frame>
    <ipd_access_criteria>via the CI</ipd_access_criteria>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Simvastatin 80mg OD</title>
          <description>Simvastatin: 80mg simvastatin oral once daily for 24 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Oral placebo tablet once daily for 24 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Simvastatin 80mg OD</title>
          <description>Simvastatin: 80mg simvastatin oral once daily for 24 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Oral placebo tablet once daily for 24 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.5" spread="7.0"/>
                    <measurement group_id="B2" value="51.1" spread="6.8"/>
                    <measurement group_id="B3" value="51.3" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Whole Brain Volume</title>
        <time_frame>24 months</time_frame>
        <population>1 participant had a missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 80mg OD</title>
            <description>Simvastatin: 80mg simvastatin oral once daily for 24 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Oral placebo tablet once daily for 24 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Whole Brain Volume</title>
          <population>1 participant had a missing data</population>
          <units>percentage of brain volumen change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.288" spread="0.521"/>
                    <measurement group_id="O2" value="0.584" spread="0.498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>intention-to-treat analysis</non_inferiority_desc>
            <p_value>0.003</p_value>
            <method>BBSI=brain boundary shift integral</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Disability (EDSS).</title>
        <description>Score (0 to 10), lower score less disability and better progression. For EDSS, mean score at 24 months was compared between treatment groups using an ANCOVA model adjusting for baseline score and minimisation variables.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 80mg OD</title>
            <description>Simvastatin: 80mg simvastatin oral once daily for 24 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Oral placebo tablet once daily for 24 months</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Disability (EDSS).</title>
          <description>Score (0 to 10), lower score less disability and better progression. For EDSS, mean score at 24 months was compared between treatment groups using an ANCOVA model adjusting for baseline score and minimisation variables.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.93" spread="1.11"/>
                    <measurement group_id="O2" value="6.35" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>EDSS,mean score at 24 months was compared between treatment groups using an ANCOVA model adjusting for baseline score and minimisation variables.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>EDSS,mean score at 24 months was compared between treatment groups using an ANCOVA model adjusting for baseline score and minimisation variables.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Disability (MSFC Z Score).</title>
        <description>Negative value implies worsening and a positive value implies improvement.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 80mg OD</title>
            <description>Simvastatin: 80mg simvastatin oral once daily for 24 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Oral placebo tablet once daily for 24 months</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Disability (MSFC Z Score).</title>
          <description>Negative value implies worsening and a positive value implies improvement.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="2.06"/>
                    <measurement group_id="O2" value="-1.21" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Disability (MSFC Walk).</title>
        <description>The patient is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the patient has reached the 25-foot mark.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 80mg OD</title>
            <description>Simvastatin: 80mg simvastatin oral once daily for 24 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Oral placebo tablet once daily for 24 months</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Disability (MSFC Walk).</title>
          <description>The patient is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the patient has reached the 25-foot mark.</description>
          <units>foot per second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="1.61"/>
                    <measurement group_id="O2" value="1.55" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Disability (MSFC Peg Test).</title>
        <description>The patient is seated at a table with a small, shallow container holding nine pegs and a wood or plastic block containing nine empty holes. On a start command when a stopwatch is started, the patient picks up the nine pegs one at a time as quickly as possible, puts them in the nine holes, and, once they are in the holes, removes them again as quickly as possible one at a time, replacing them into the shallow container. The total time to complete the task is recorded.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 80mg OD</title>
            <description>Simvastatin: 80mg simvastatin oral once daily for 24 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Oral placebo tablet once daily for 24 months</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Disability (MSFC Peg Test).</title>
          <description>The patient is seated at a table with a small, shallow container holding nine pegs and a wood or plastic block containing nine empty holes. On a start command when a stopwatch is started, the patient picks up the nine pegs one at a time as quickly as possible, puts them in the nine holes, and, once they are in the holes, removes them again as quickly as possible one at a time, replacing them into the shallow container. The total time to complete the task is recorded.</description>
          <units>speed per second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.033" spread="0.010"/>
                    <measurement group_id="O2" value="0.033" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Disability (MSFC PASAT).</title>
        <description>The PASAT is a measure of cognitive function that assesses auditory information processing speed and flexibility, as well as calculation ability. Single digits are presented every 3 seconds and the patient must add each new digit to the one immediately prior to it. Shorter inter-stimulus intervals, e.g., 2 seconds or less have also been used with the PASAT but tend to increase the difficulty of the task. Score 0 to 60, higher score less disability.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 80mg OD</title>
            <description>Simvastatin: 80mg simvastatin oral once daily for 24 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Oral placebo tablet once daily for 24 months</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Disability (MSFC PASAT).</title>
          <description>The PASAT is a measure of cognitive function that assesses auditory information processing speed and flexibility, as well as calculation ability. Single digits are presented every 3 seconds and the patient must add each new digit to the one immediately prior to it. Shorter inter-stimulus intervals, e.g., 2 seconds or less have also been used with the PASAT but tend to increase the difficulty of the task. Score 0 to 60, higher score less disability.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" spread="15.4"/>
                    <measurement group_id="O2" value="35.2" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Impact Specific to the Disease and Rated by the Patient (MSIS-29 Questionnaire Total Score)</title>
        <description>The MSIS-29 is a 29-item self-report measure with 20 items associated with a physical scale and 9 items with a psychological scale. Items ask about the impact of MS on day-to-day life in the past two weeks. All items have 5 response options: 1 &quot;not at all&quot; to 5&quot;extremely&quot;. Each of the two scales is scored by summing the responses across items, then converting to a 0-100 scale where 100 indicates a greater impact of the disease on daily function (worse health).</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 80mg OD</title>
            <description>Simvastatin: 80mg simvastatin oral once daily for 24 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Oral placebo tablet once daily for 24 months</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Impact Specific to the Disease and Rated by the Patient (MSIS-29 Questionnaire Total Score)</title>
          <description>The MSIS-29 is a 29-item self-report measure with 20 items associated with a physical scale and 9 items with a psychological scale. Items ask about the impact of MS on day-to-day life in the past two weeks. All items have 5 response options: 1 &quot;not at all&quot; to 5&quot;extremely&quot;. Each of the two scales is scored by summing the responses across items, then converting to a 0-100 scale where 100 indicates a greater impact of the disease on daily function (worse health).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.1" spread="15.6"/>
                    <measurement group_id="O2" value="76.1" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Impact Specific to the Disease and Rated by the Patient (MSIS-29 Questionnaire Physical Score)</title>
        <description>The MSIS-29 is a 29-item self-report measure with 20 items associated with a physical scale and 9 items with a psychological scale. Items ask about the impact of MS on day-to-day life in the past two weeks. All items have 5 response options: 1 &quot;not at all&quot; to 5&quot;extremely&quot;. Each of the two scales are scored by summing the responses across items, then converting to a 0-100 scale where 100 indicates greater impact of disease on daily function (worse health).</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 80mg OD</title>
            <description>Simvastatin: 80mg simvastatin oral once daily for 24 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Oral placebo tablet once daily for 24 months</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Impact Specific to the Disease and Rated by the Patient (MSIS-29 Questionnaire Physical Score)</title>
          <description>The MSIS-29 is a 29-item self-report measure with 20 items associated with a physical scale and 9 items with a psychological scale. Items ask about the impact of MS on day-to-day life in the past two weeks. All items have 5 response options: 1 &quot;not at all&quot; to 5&quot;extremely&quot;. Each of the two scales are scored by summing the responses across items, then converting to a 0-100 scale where 100 indicates greater impact of disease on daily function (worse health).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" spread="11.4"/>
                    <measurement group_id="O2" value="56.3" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Impact Specific to the Disease and Rated by the Patient (MSIS-29 Questionnaire Psychological Score)</title>
        <description>The MSIS-29 is a 29-item self-report measure with 20 items associated with a physical scale and 9 items with a psychological scale. Items ask about the impact of MS on day-to-day life in the past two weeks. All items have 5 response options: 1 &quot;not at all&quot; to 5&quot;extremely&quot;. Each of the two scales is scored by summing the responses across items, then converting to a 0-100 scale where 100 indicates a greater impact of the disease on daily function (worse health).</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 80mg OD</title>
            <description>Simvastatin: 80mg simvastatin oral once daily for 24 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Oral placebo tablet once daily for 24 months</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Impact Specific to the Disease and Rated by the Patient (MSIS-29 Questionnaire Psychological Score)</title>
          <description>The MSIS-29 is a 29-item self-report measure with 20 items associated with a physical scale and 9 items with a psychological scale. Items ask about the impact of MS on day-to-day life in the past two weeks. All items have 5 response options: 1 &quot;not at all&quot; to 5&quot;extremely&quot;. Each of the two scales is scored by summing the responses across items, then converting to a 0-100 scale where 100 indicates a greater impact of the disease on daily function (worse health).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" spread="5.8"/>
                    <measurement group_id="O2" value="19.8" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Collected over 24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Simvastatin 80mg OD</title>
          <description>Simvastatin: 80mg simvastatin oral once daily for 24 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Oral placebo tablet once daily for 24 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Lesion Biopsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Appendectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 relapse (requiring hospital admission)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Increased spasticity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Sub-arachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Viral encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pain</sub_title>
                <description>pain</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary infection</sub_title>
                <description>UTI</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <description>headache</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Relapse</sub_title>
                <description>relapse of MS</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>cramp</sub_title>
                <description>cramp</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>worsening mobility</sub_title>
                <description>worsening mobility</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>increase spasticity</sub_title>
                <description>spasticity</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Jeremy Chataway, Chief Investigator</name_or_title>
      <organization>University of London</organization>
      <phone>07974752295</phone>
      <email>j.chataway@ucl.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

